Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$2.23 -0.7%	$1.76	$1.03 ▼ $2.64	$441.75M	1.48	1.69 million shs	577,932 shs
MREO Mereo BioPharma Group	$2.81 +1.6%	$2.38	$1.58 ▼ $5.02	$446.00M	0.47	1.10 million shs	495,232 shs
PGEN Precigen	$1.49 -3.6%	$1.42	$0.65 ▼ $2.17	$441.29M	1.84	1.35 million shs	857,628 shs
PLX Protalix BioTherapeutics	$1.44 +0.3%	$2.11	$0.82 ▼ $3.10	$114.24M	-0.21	557,461 shs	156,038 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	+6.16%	-1.75%	+35.76%	+65.93%	+63.50%
MREO Mereo BioPharma Group	0.00%	+4.15%	+23.21%	+9.09%	-35.06%
PGEN Precigen	+1.32%	+2.67%	+6.21%	-7.78%	-5.52%
PLX Protalix BioTherapeutics	-4.03%	-7.14%	-14.37%	-39.15%	+25.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	3.1254 of 5 stars	3.7	3.0	0.0	2.7	2.5	0.6
MREO Mereo BioPharma Group	2.0241 of 5 stars	3.6	1.0	0.0	3.4	1.7	0.0
PGEN Precigen	4.1785 of 5 stars	3.5	1.0	4.7	3.9	1.7	0.6
PLX Protalix BioTherapeutics	2.8083 of 5 stars	3.5	4.0	0.0	1.1	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.33	Buy	$8.67	289.51% Upside
MREO Mereo BioPharma Group	3.17	Buy	$7.67	173.32% Upside
PGEN Precigen	3.00	Buy	$6.00	304.04% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	945.30% Upside

Current Analyst Ratings Breakdown

Latest PLX, PGEN, ATAI, and MREO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/20/2025	ATAI Atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/13/2025	ATAI Atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
3/26/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/20/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$1.86M	239.27	N/A	N/A	$1.47 per share	1.51
MREO Mereo BioPharma Group	$1M	446.00	N/A	N/A	$0.36 per share	7.79
PGEN Precigen	$4.20M	104.34	N/A	N/A	$0.48 per share	3.09
PLX Protalix BioTherapeutics	$59.76M	1.91	$0.08 per share	17.80	$0.47 per share	3.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.91	N/A	N/A	N/A	N/A	-65.75%	-52.71%	8/12/2025 (Estimated)
MREO Mereo BioPharma Group	-$29.47M	-$0.07	N/A	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
PGEN Precigen	-$95.90M	-$0.56	N/A	N/A	N/A	-3,521.68%	-123.06%	-87.33%	8/13/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.63	N/A	-21.03%	-30.89%	-11.74%	N/A

Latest PLX, PGEN, ATAI, and MREO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A
3/19/2025	Q4 2024	PGEN Precigen	-$0.06	-$0.04	+$0.02	-$0.06	$1.30 million	$1.19 million
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
MREO Mereo BioPharma Group	N/A	6.10	6.10
PGEN Precigen	N/A	1.63	1.63
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
MREO Mereo BioPharma Group	62.83%
PGEN Precigen	33.51%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	26.80%
MREO Mereo BioPharma Group	5.50%
PGEN Precigen	47.10%
PLX Protalix BioTherapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	200.34 million	115.45 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	148.74 million	Optionable
PGEN Precigen	190	295.18 million	161.37 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable

PLX, PGEN, ATAI, and MREO Headlines

Recent News About These Companies

Northern Trust Corp Has $1.38 Million Stock Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)

May 29, 2025 | marketbeat.com

Q1 Earnings Estimate for PLX Issued By HC Wainwright

May 27, 2025 | marketbeat.com

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025 | finance.yahoo.com

PLX: First Quarter Results

May 13, 2025 | msn.com

Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges

May 10, 2025 | uk.investing.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 10, 2025 | finanznachrichten.de

Protalix BioTherapeutics Q1 Earnings Preview

May 10, 2025 | msn.com

1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings Preview

May 10, 2025 | benzinga.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth

May 9, 2025 | proactiveinvestors.com

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 9, 2025 | prnewswire.com

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

May 6, 2025 | seekingalpha.com

Why Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.71%

April 15, 2025 | aaii.com

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

April 10, 2025 | seekingalpha.com

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

March 24, 2025 | finance.yahoo.com

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?

March 22, 2025 | msn.com

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI

March 21, 2025 | proactiveinvestors.com

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

March 20, 2025 | markets.businessinsider.com

Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript

March 19, 2025 | seekingalpha.com

Amended: Protalix Annual Earnings Fall

March 19, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, PGEN, ATAI, and MREO Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$2.22 -0.02 (-0.67%)

As of 12:02 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Mereo BioPharma Group NASDAQ:MREO

$2.80 +0.05 (+1.63%)

As of 12:02 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Precigen NASDAQ:PGEN

$1.48 -0.06 (-3.57%)

As of 12:02 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Protalix BioTherapeutics NYSE:PLX

$1.44 +0.01 (+0.35%)

As of 12:02 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time